AHA/ASA: Treat all patients with suspected CVST due to a COVID-19 vaccine with non-heparin anticoagulants |
Editorial
eMediNexus Coverage from: 
AHA/ASA: Treat all patients with suspected CVST due to a COVID-19 vaccine with non-heparin anticoagulants

0 Read Comments                

The American Heart Association (AHA)/American Stroke Association (ASA) Stroke Council leadership has issued guidelines on the management of cerebral venous sinus thrombosis (CVST) with vaccine-induced immune thrombotic thrombocytopenia (VITT), which have been published in the journal Stroke.Let’s first understand the definitions of these terms.CVST is formation of clots in the veins (cf. in most cases of stroke, clots are formed in the arteries of the brain).CVST and thrombocytopenia together are called thrombosis-thrombocytopenia syndrome (TTS).When TTS is linked to receiving a COVID-19 vaccine, it is called vaccine-induced immune thrombotic thrombocytopenia (VITT). CVST may be roughly divided into four syndromes: isolated headache or increased intracranial pressurefocal neurological presentationssubacute encephalopathycavernous sinus syndrome/multiple cranial neuropathi...
To Read or comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now